Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 4, 2010, Pages 1347-1351

  Milner, Erin ^a   McCalmont, William ^a   Bhonsle, Jayendra ^a   Caridha, Diana ^a   Carroll, Dustin ^a   Gardner, Sean ^a   Gerena, Lucia ^a   Gettayacamin, Montip ^b   Lanteri, Charlotte ^a   Luong, ThuLan ^a   Melendez, Victor ^a   Moon, Jay ^a   Roncal, Norma ^a   Sousa, Jason ^a   Tungtaeng, Anchalee ^b   Wipf, Peter ^c   Dow, Geoffrey ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b U S ARMY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antimalarials; Mefloquine; Plasmodium berghei; Plasmodium falciparum; Quinoline methanol; Structure activity relationship

Indexed keywords

ANTIMALARIAL AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WR 176990; WR 177000; WR 183544; WR 183545; WR 308245; WR 308246; WR 308251; WR 308252; WR 308253; WR 308254; WR 308257; WR 308277; WR 308278; WR 308314; WR 308396; WR 308412; WR 308437; WR 308607; WR 308622; WR 308623; WR 308626; WR 308633; WR 308653; WR 308763; WR 308764; WR 319535; WR 319581;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; IC 50; LIVER MICROSOME METABOLISM; MACROPHAGE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, FUNGAL; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR STRUCTURE; PLASMODIUM FALCIPARUM; QUINOLINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 75449091246     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.001     Document Type: Article

References (27)

1. http://www.childinfo.org/malaria.html.
2. Wells T.N.C., Alonso P.L., and Gutteridge W.E. Nat. Rev. 8 (2009) 879
3. http://www.cdc.gov/malaria/travel/drugs_pregnant_hcp.html.
4. Tin F., Hlaing N., and Lasserre R. Bull. WHO 60 (1982) 913
5. Weinke T., Trautmann M., Held T., Weber G., Eichenlaub D., Fleischer K., Kern W., and Pohle H.D. Am. J. Trop. Med. Hyg. 45 (1991) 86
6. Hennequin C., Bourée P., Bazin N., Bisaro F., and Feline A. Arch. Intern. Med. 154 (1994) 2360
7. Schlagenhauf P., Steffen R., Lobel H., Johnson R., Letz R., Tschopp A., Vranjes N., Bergqvist Y., Ericsson O., Hellgren U., Rombo L., Mannino S., Handschin J., and Stürchler D. Trop. Med. Int. Health 1 (1996) 485
8. Trenholme C., Williams R., Desjardines R., Frischer H., Carson P., Riechmann K., and Canfield C. Science 190 (1975) 792
9. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., and Bertino J.R. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 695
10. Riffkin C.D., Chung R., Wall D.M., Zalcberg J.R., Cowman A.F., Foley M., and Tilley L. Biochem. Pharmacol. 52 (1996) 1545
11. Jones R., Kunsman G., Levine B., Smith M., and Stahl C. Forensic Sci. Int. 68 (1994) 29
12. Pham Y.T., Nosten F., Farinotti R., White N.J., and Gimenez F. Int. J. Clin. Pharmacol. Ther. 37 (1999) 58
13. Dow G., Heady T., Bhattacharjee A., Caridha D., Gerena L., Gettayacamin M., Lanteri C., Obaldia III N., Roncal N., Shearer T., Smith P., Tungtaeng A., Wolf L., Cabezas M., Yourick D., and Smith K. Antimicrob. Agents Chemother. 50 (2006) 4132
14. T.R. Sweeny, A Survey of Compounds from the Antimalarials Drug Development Program of the US Army Medical Research and Development Command, Vol. I, 1991, 41-117.
15. Wipf P., Mo T., Geib S., Caridha D., Dow G., Gerena L., Roncal N., and Milner E. Org. Biomol. Chem. 7 (2009) 4163
16. Manuscript outlining the relationship between biological data and physiochemical properties is under review and we anticipate it's publication in the near future.
17. Detailed synthetic procedures and screening methods are outlined in the Supplementary data accompanying this article.
18. Blumbergs P., Ao M.S., LaMontagne M.P., and Markovac A. J. Med. Chem. 18 (1975) 1122
19. Littke A., Schwarz L., and Fu G. J. Am. Chem. Soc. 124 (2002) 6343
20. Duncton M., and Pattenden G. J. Chem. Soc., Perkin Trans. 1 (1999) 1235
21. Ruano J.L.G., Fajardo C., Fraile A., and Martin M.R. J. Org. Chem. 70 (2005) 4300
22. Legrand E., Volney B., Meynard J.B., Mercereau-Puijalon O., and Esterre P. Antimicrob. Agents Chemother. 52 (2008) 288
23. Schlitzer M. ChemMedChem 2 (2007) 944
24. Mu J.Y., Israili Z.H., and Dayton P.G. Drug Metab. Dispos. 3 (1975) 198
25. Desneves J., Thorn G., Berman A., Galatis D., La Greca N., Sinding J., Foley M., Deady L.W., Cowman A.F., and Tilley L. Mol. Biochem. Parasitol. 82 (1996) 181
26. Schwartz D.E., Eckert G., Hartmann D., Weber B., Richard-Lenoble D., Ekue J.M., and Gentilini M. Chemotherapy 28 (1982) 70
27. E. Kerns, Li. Di, Drug-like Properties: Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization, Elsevier, 2008. ISBN-13: 978-0-12-369520-8.